AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JAN 8 - (NewsRx.com & NewsRx.net) -- According to a study from the United States, "TCR Id protein conjugated to keyhole limpet hemocyanin (KLH) (TCR Id:KLH) and injected with a chemical adjuvant (QS-21) induces a protective, Id-specific immune response against the murine T-cell lymphoma, C6VL. However, Id-based immunotherapy of C6VL has not demonstrated therapeutic efficacy in tumor-bearing mice."
University of Michigan immunologists "report that C6VL lysate-pulsed dendritic cells (C6VL-DC) vaccines display enhanced efficacy in both the prevention and the therapy of T-cell lymphoma compared with TCR Id:KLH with QS-21 vaccines."
According to E. Gatza and colleagues, "C6VL-DC vaccines stimulated potent tumor-specific immunity that protected mice against lethal challenge with C6VL and significantly enhanced the survival of tumor-bearing mice.
"Tumor-specific proliferation and secretion of IFN-gamma indicative of a Th1-type immune response were observed upon ex vivo stimulation of vaccine-primed lymph node cells. Adoptive transfer of immune T-cell-enriched lymphocytes was sufficient to protect naive recipients from lethal tumor challenge."
They also found that "CD8+ T cells were absolutely required for tumor protection."
"Although C6VL-DC ...